These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 37063836)

  • 1. A close look at current γδ T-cell immunotherapy.
    Ma L; Feng Y; Zhou Z
    Front Immunol; 2023; 14():1140623. PubMed ID: 37063836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. γδ T cells: Major advances in basic and clinical research in tumor immunotherapy.
    Zhao Y; Dong P; He W; Zhang J; Chen H
    Chin Med J (Engl); 2024 Jan; 137(1):21-33. PubMed ID: 37592858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. γδ T-cell immunotherapy for lung cancer.
    Yoshida Y; Nakajima J; Wada H; Kakimi K
    Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic avenues for γδ T cells in cancer.
    Costa GP; Mensurado S; Silva-Santos B
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γδ cell-based immunotherapy for cancer.
    Lo Presti E; Corsale AM; Dieli F; Meraviglia S
    Expert Opin Biol Ther; 2019 Sep; 19(9):887-895. PubMed ID: 31220420
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential of gamma/delta T cells for solid tumor immunotherapy.
    Zhu D; Ren X; Xie W; Chen J; Liang S; Jiang M; Wang J; Zheng Z
    Front Immunol; 2024; 15():1466266. PubMed ID: 39253082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
    Li Y; Li G; Zhang J; Wu X; Chen X
    Front Immunol; 2020; 11():619954. PubMed ID: 33664732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. γδ T cell exhaustion: Opportunities for intervention.
    Chen D; Guo Y; Jiang J; Wu P; Zhang T; Wei Q; Huang J; Wu D
    J Leukoc Biol; 2022 Dec; 112(6):1669-1676. PubMed ID: 36000310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with γδ T-cells: the future is there.
    Kabelitz D; Yin Z
    Immunotherapy; 2024; 16(11):705-708. PubMed ID: 38940301
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
    Gomes AQ; Martins DS; Silva-Santos B
    Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma-delta (γδ) T cells: friend or foe in cancer development?
    Zhao Y; Niu C; Cui J
    J Transl Med; 2018 Jan; 16(1):3. PubMed ID: 29316940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
    Zhou J; Kang N; Cui L; Ba D; He W
    Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.
    Saura-Esteller J; de Jong M; King LA; Ensing E; Winograd B; de Gruijl TD; Parren PWHI; van der Vliet HJ
    Front Immunol; 2022; 13():915837. PubMed ID: 35784326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy harnessing γδ T cells and programmed death-1.
    Tanaka Y
    Immunol Rev; 2020 Nov; 298(1):237-253. PubMed ID: 32888218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy by γδ T cells.
    Hayday A; Dechanet-Merville J; Rossjohn J; Silva-Santos B
    Science; 2024 Oct; 386(6717):eabq7248. PubMed ID: 39361750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. γδ T Cells: The Ideal Tool for Cancer Immunotherapy.
    Yazdanifar M; Barbarito G; Bertaina A; Airoldi I
    Cells; 2020 May; 9(5):. PubMed ID: 32456316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
    Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
    Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases.
    Lopez RD
    Immunol Res; 2002; 26(1-3):207-21. PubMed ID: 12403359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.